Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 275 for:    Betamethasone

India Dexamethasone and Betamethasone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03668860
Recruitment Status : Active, not recruiting
First Posted : September 13, 2018
Last Update Posted : May 29, 2019
Sponsor:
Collaborators:
Bill and Melinda Gates Foundation
Syngene International
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati

Brief Summary:
An open label, randomized, two-period, crossover, study to compare the pharmacokinetics and pharmacodynamics of single dose Dexamethasone and Betamethasone administered orally and intramuscularly in 48 healthy, adult, female subjects under fasting conditions. This study is being conducted in Bangalore, India.

Condition or disease Intervention/treatment Phase
Preterm Birth Antenatal Corticosteroids Drug: Dexamethasone 4 mg/ml Drug: Betamethasone 4 mg/ml Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection Drug: Dexamethasone Oral Tablet Drug: Betamethasone Oral Tablet Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Randomized Study to Compare the Pharmacokinetics and Pharmacodynamics of Single Dose Dexamethasone and Betamethasone Administered Orally and Intramuscularly in Healthy Female Subjects
Actual Study Start Date : September 20, 2018
Actual Primary Completion Date : February 28, 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Active Comparator: Treatments A & B (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))

(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))

Drug: Dexamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)

Drug: Betamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)

Active Comparator: Treatments B & A (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))

(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))

Drug: Dexamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)

Drug: Betamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)

Active Comparator: Treatments C & D (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))

(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)

Drug: Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Active Comparator: Treatments D & C (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))

Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)

Drug: Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Active Comparator: Treatments E & D (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

Drug: Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Drug: Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Active Comparator: Treatments D & E (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))

Drug: Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Drug: Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Active Comparator: Treatments C & E (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)

E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)

Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)

Drug: Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)

Active Comparator: Treatments E & C (6 subjects)

After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.

Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.

E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)

C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)

Drug: Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)

Drug: Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)




Primary Outcome Measures :
  1. Measurements of pharmacokinetic parameters of each drug [ Time Frame: 23 days ]
    Plasma concentration versus time curves of Dexamethasone and Betamethasone given orally and intramuscularly to non-pregnant females.

  2. Measurements of pharmacodynamic parameters of each drug [ Time Frame: 23 days ]
    Measurements of glucose, cortisol and lymphocyte population changes versus time resulting from the steroid treatment given orally and intramuscularly to non-pregnant females.


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 23 days ]
    To monitor the adverse events and to ensure the safety of the subjects. Safety assessments will be analyzed descriptively. All continuous variables will be summarized using the following descriptive statistics: n, mean, standard deviation, median, minimum value, and maximum value. Categorical variables will be summarized using frequency counts and percentages. No formal statistical inferences are planned.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. - Healthy, adult, female subjects within the age range of 18 to 40 years [both inclusive].
  2. - Weight not less than 45 kg.
  3. - BMI [18.00 to 25.00 kg/m2] [both inclusive].
  4. - Willingness to provide written informed consent to participate in the study.
  5. - Without any medical or surgical condition that might interfere with gastrointestinal absorption of the study drug.
  6. - Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray [PA view].
  7. - Subjects should be non-smoker or moderate smokers (less than 10 cigarettes a day), and should not be consuming tobacco containing products [ defined as someone who has stopped smoking for a year from the date of screening].
  8. - Subject must be either a non-drinker or an occasional drinker of alcohol and agreed to abstain from alcoholic consumption during the study duration.
  9. - Absence of disease markers of HIV I and 2, Hepatitis Band C and Syphilis.
  10. - Female subjects of childbearing potential must be using two acceptable methods of contraception, ( e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, progestin only implants and long acting injectables (Depo Provera), etc.). These measures are required during the study and for at least two weeks after the last dose and conveyed during the inform consent process (or) postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).
  11. - Subject should be literate.

Exclusion Criteria:

  1. - History or presence of significant: Cardiovascular, pulmonary, hepatic, renal, hematological, gastro- intestinal, endocrine, immunologic, dermatologic, neurological, HEENT (Head, Eyes, Ears, Nose And Throat), psychiatric disease/ disorder.
  2. - History or presence of significant:

    • Asthma, urticaria or other allergic type reactions or hypersensitivity after taking Dexamethasone or Betamethasone or any other drug.
    • Ulceration or history of gastric and / or duodenal ulcer.
    • Stomach or intestinal bleeding.
    • Jaundice in the past 6 months.
  3. - History of drug abuse.
  4. - History of renal impairment or severe hepatic impairment.
  5. - History or presence of psychiatric disorders
  6. - Have donated 500 mL or more blood within 90 days before receiving the first dose of study drug.
  7. - Major illness during 3 months before screening.
  8. - Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
  9. - Any difficulty in accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
  10. - Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period and for at least 10 h before and at least 4 h after collecting the baseline assessment blood sample in Period 1.
  11. - Refuse to abstain from fluid for at least 1 h before and 1 h after dosing.
  12. - Refuse to abstain from alcohol for the duration of the study.
  13. - Positive during breath alcohol test.
  14. - Positive during urine drug screening.
  15. - History of difficulty in swallowing study formulations.
  16. - Received any medication [including over-the-counter products, vitamins, herbal products] for 14 days preceding the study.
  17. - Use of enzyme modifying drugs, MAO inhibitors within 30 days prior to receiving the first dose of study medication.
  18. - History of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in of each period.
  19. - Consumption of xanthine containing food and beverages (chocolates, tea, coffee or cola drinks) for at least 48 hours prior to study check-in.
  20. - Consumption of grapefruit juice within the 7-days prior to study check-in.
  21. - Pregnant females as determined by positive test for pregnancy.
  22. - Lactating females.
  23. - Investigator/physician feels that it is not in the subject's and/or study's best interest to enroll the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03668860


Locations
Layout table for location information
India
Syngene International Limited, Tower I
Bangalore, India, 560 100
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Bill and Melinda Gates Foundation
Syngene International
Investigators
Layout table for investigator information
Study Director: Alan Jobe, MD, Ph.D Children's Hospital Medical Center, Cincinnati

Layout table for additonal information
Responsible Party: Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03668860     History of Changes
Other Study ID Numbers: CIN001 - India Steroids
First Posted: September 13, 2018    Key Record Dates
Last Update Posted: May 29, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Children's Hospital Medical Center, Cincinnati:
Antenatal Corticosteroids
Betamethasone
Dexamethasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone acetate phosphate
Betamethasone sodium phosphate
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Dexamethasone
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Asthmatic Agents
Respiratory System Agents
Bronchodilator Agents